Fig. 2

Tofacitinib downregulates gene expression of MX1 at baseline or in the presence of IFN-γ or IL-29. Keratinocytes (n = 5–8) were stimulated for 60 min with tofacitinib before addition of the respective cytokine or bacterial component. MX gene expression is shown for controls (a), tofacitinib in combination with LPS or LTA (b), in combination with IL-17 or IL-22 (c), or tofacitinib combined with IFN-γ or IL-29 (d). The cell lysates were analysed via qPCR. Statistical calculation was done using the Mann-Whitney U test. Significances that were compared to the untreated control are depicted directly above the stimulatory agent or the compared conditions are indicated by lines and depicted as follows: *P ≤ 0.05, **P ≤ 0.01, and ***P ≤ 0.001